These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33407562)

  • 1. Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective.
    van Santen DK; Coutinho RA; van den Hoek A; van Brussel G; Buster M; Prins M
    Harm Reduct J; 2021 Jan; 18(1):2. PubMed ID: 33407562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
    van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
    Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial.
    van Santen DK; Boyd A; Matser A; Maher L; Hickman M; Lodi S; Prins M
    Addiction; 2021 Nov; 116(11):3115-3126. PubMed ID: 33788326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
    Bernard CL; Rao IJ; Robison KK; Brandeau ML
    PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015.
    van Santen DK; van der Helm JJ; Lindenburg K; Schim van der Loeff M; Prins M
    Int J Drug Policy; 2017 Sep; 47():95-101. PubMed ID: 28606392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs.
    Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Turcotte MÈ; Bruneau J
    Am J Prev Med; 2020 Jun; 58(6):845-853. PubMed ID: 32444003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.
    Fernandes RM; Cary M; Duarte G; Jesus G; Alarcão J; Torre C; Costa S; Costa J; Carneiro AV
    BMC Public Health; 2017 Apr; 17(1):309. PubMed ID: 28399843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
    de Vos AS; van der Helm JJ; Matser A; Prins M; Kretzschmar ME
    Addiction; 2013 Jun; 108(6):1070-81. PubMed ID: 23347124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
    Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
    Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
    Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
    Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention knowledge, risk behaviours and seroprevalence among nonurban injectors of southwest Connecticut.
    Grau LE; Zhan W; Heimer R
    Drug Alcohol Rev; 2016 Sep; 35(5):628-36. PubMed ID: 27073014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.
    Auriacombe M; Roux P; Briand Madrid L; Kirchherr S; Kervran C; Chauvin C; Gutowski M; Denis C; Carrieri MP; Lalanne L; Jauffret-Roustide M;
    BMJ Open; 2019 Feb; 9(2):e023683. PubMed ID: 30796121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth.
    Stone KA
    Harm Reduct J; 2015 Oct; 12():32. PubMed ID: 26472335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique.
    Semá Baltazar C; Kellogg TA; Boothe M; Loarec A; de Abreu E; Condula M; Fazito E; Raymond HF; Temmerman M; Luchters S
    Int J Drug Policy; 2021 Apr; 90():103095. PubMed ID: 33429163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injection risk norms and practices among migrant Puerto Rican people who inject drugs in New York City: The limits of acculturation theory.
    Gelpí-Acosta C; Guarino H; Benoit E; Deren S; Pouget ER; Rodríguez A
    Int J Drug Policy; 2019 Jul; 69():60-69. PubMed ID: 31196730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.